I believe it was wise for IPIX to PR a statement
I believe it was wise for IPIX to PR a statement regarding the DoD conference cancelation. The fact that the conference was cancelled due to an explosion of the Delta variant is just another proof point for the dire need for an effective CV19 therapeutic. Leo took the opportunity to remind investors that Brilacidin continues to show consistently positive in vitro results against a wide variety of viruses. Delta virus testing is in the queue and IMO will show the same result that Brilacidin penetrates the viral wall and destroys the virus. There will most likely be some real world proof points as well with some of the Russian patients treated in the human trial that likely had the Delta variant.
If you google some of the tested H-CoV strains mentioned in today’s PR (OC43, 229E, NL63), they are species of coronavirus responsible for bronchiolitis, croup, upper and lower respiratory tract infections including pneumonia, and are among the known viruses that cause the common cold. What do you think the overall market is for treating these conditions? Do you think there might be some interest to quickly fund and develop other delivery methods such as an inhaler to address these common ailments and diseases?
IMO the DoD is completely aware of Brilacidin as a Bio Defense asset. They are anxiously awaiting B-CV19 human trial results for final confirmation like all of us investors are. What is clear from today’s PR is that if trial results are positive, there will be enormous demand to fund, procure, partner and accelerate Brilacidin to market.
I expect that IPIX will soon PR that the human trial database has been locked. Within a month or so we will get top line results. My bet is that results will be somewhere in the very good to excellent range. There are many proof points including previous Brilacidin human trials, exhaustive RBL testing specific to CV19, extraordinary Selectivity Index, unique virocidal MOA (penetrates viral wall and kills the virus) and a continual safety profile including the DMC green light to increase frequency dosing form 3 to 5 days.
I understand that some investors are impatient. I initiated my position in CTIX 10 years ago. Investors have experienced blatant criminal attacks on IPIX for over 6 years. Our time is coming very soon. IMO we are part owners of a drug that will save millions of people worldwide and have significant economic impact. We will have confirmation of this very soon and I believe that is when the fun just begins.
13
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A Well-Earned Accolade in Franchising When you've got your finger on the pulse of the franchise business, it’s hard to ignore the likes of Rebecca Grovenstein snagging the IFA Franchisee of the Year award. Running a business ain't for the faint of heart, let alone steering multiple franchises to success. Grovenstein's operations of Lightbridge Academy in Apex and Holly...
Continue Reading
Popping Corks for Creativity: Decoy's New Chapter Stepping outside the vines and into the artistic limelight, Decoy Wines is shaking up the status quo. Announcing the launch of the Pour to What's Possible Grant, the brand is throwing down $10,000 to back creatives itching to make waves in entertainment. Now, doesn't that stand out? The Grit Behind the Grapes: Decoy's...
Continue Reading
The K-Royal Culture Festival is rolling out in Fall 2026 with a flair that promises to capture the globetrotters' imaginations and then some. South Korea's signature national heritage jamboree is popping off from October 7 through October 11, 2026, at four magnificent palaces and the Jongmyo Shrine. If you're into discovering the depths of a place's history through...
Continue Reading
New Frontiers in Lung Cancer Treatment Well, here's a story that rattles the cage in the oncology world. The name of the game is ivonescimab, Akeso’s latest move as they toss their hat into the already crowded yet pivotal lung cancer treatment ring. This isn't just some side hustle—they've got Phase III data pointin' straight north, figuratively casting a shadow over...
Continue Reading
Traders buckle up! GenesisFX Markets just kicked open a new chapter in forex and CFD trading with their Live Leaderboards and beefed-up social trading tools. What's the commotion about? Well, that's your hook. These leaderboards are the newest addition to their ecosystem, paired with some serious social trading muscle. As Arkadiusz Bujalski, the Head of Ops and System...
Continue Reading
The Future of Education Shaped Today There's a profound shift happening in higher education, and it's not the usual undergrad grind most folks think of. Cate Tolnai, stepping into her role at the University of Phoenix, is in the thick of it. She's set to join the UPCEA Council for Credential Innovation's leadership team, and that isn't some fluff title. Her appointment...
Continue Reading
Digging Deeper with AI in M&A Deals Picture this: you’re at the table with a fat corporate M&A deal, eyes darting as you decipher numbers and nods, when out swings Plan A Technologies with their new ace up their sleeve—a stealth AI assessment tool armed to sharpen their technical due diligence. Unmasking the Tech Jigsaw Las Vegas-based Plan A Technologies hasn't just...
Continue Reading
Unearthing the Secrets of High Valley AVA Brassfield Estate Winery, tucked away in Northern California's Lake County, is setting the wine world abuzz with its unique approach to Cabernet Sauvignon. As they celebrate International Cabernet Sauvignon Day, it's a chance to spotlight the magic that their High Valley terroir brings to the table. The Allure of High-Altitude...
Continue Reading
Veteran suicide is a crisis staring us square in the face, with rates 60% higher than the general population. It's a grim reminder that the mental toll on those who've served is a deep chasm hard to bridge. Cohen Veterans Network (CVN) is stepping up to the plate with a new campaign dubbed 'Ask Anyway: Conversations to Save a Life'. This isn't just any awareness...
Continue Reading
Legal Storm Brewing Around Geron Corporation Ah, the familiar smell of trouble in corporate paradise, and this time it's drifting from Geron Corporation (NASDAQ: GERN). If you've got your chips on the table with these guys, you'd better pony up and listen up. Kuehn Law, PLLC is lighting a fire under Geron's board, snooping on whether their head honchos scuttled their...
Continue Reading
Top 5 Most Recently Viewed Articles
Impact of Federal Scrutiny on Corporate Philanthropy Strategies In a climate marked by increasing federal scrutiny on Diversity, Equity, and Inclusion (DEI), a recent survey shared some eye-opening insights from corporate philanthropy leaders. This research indicates that roughly 55% of these leaders believe that federal pressures are reshaping their corporate giving...
Continue Reading
S&P Global Leadership to Share Insights at Investor Conference Martina Cheung, the President and Chief Executive Officer of S&P Global (NYSE: SPGI), is set to participate in a significant event known as Raymond James' Institutional Investors Conference. Cheung's presentation is scheduled for a time slot that allows for extensive engagement with institutional investors,...
Continue Reading
CPI Aerostructures Welcomes Paula Castellano to Leadership Team CPI Aerostructures, Inc. (NYSE: CVU) has recently made an exciting addition to its leadership team with the appointment of Paula Castellano as Senior Vice President, Operations. This strategic move highlights the company's ongoing commitment to excellence in the aerospace manufacturing sector. Paula...
Continue Reading
ScanTech AI Systems Secures Nasdaq Compliance ScanTech AI Systems Inc. (NASDAQ: STAI), a prominent player in AI-enhanced security screening, has successfully met Nasdaq's compliance requirements for publicly held shares. This achievement demonstrates the company’s resilience and ongoing efforts to strengthen its market position. Details on Compliance Notification...
Continue Reading
AMD Challenges Amid Competition Shares of Advanced Micro Devices Inc (NASDAQ: AMD) continue to experience downward pressure, influenced by a wave of competition from key market players. The latest movements follow an investment by Intel Corp (NASDAQ: INTC) from a prominent shareholder. This situation highlights the ongoing tension within the semiconductor landscape. The...
Continue Reading